目的：检测高尔基磷蛋白3（Golgi phosphoprotein 3, GOLPH3）在人非小细胞肺癌（non-small cell lung cancer，NSCLC）组织及癌旁肺组织中的表达，探讨GOLPH3表达与非小细胞肺癌临床病理特征及预后中的意义。方法：选取2004年2月至2006年2月在山东大学齐鲁医院胸外科行手术治疗的116例NSCLC患者组织标本及43例癌旁肺组织标本，采用免疫组化方法检测NSCLC组织和癌旁肺组织标本中GOLPH3蛋白表达水平，采用SPSS 13.0软件对数据进行统计学分析。结果：与癌旁肺组织相比，肺癌组织中GOLPH3蛋白的阳性表达率明显增高\[57.8%（67/116）vs 28.0%（12/43），P<001\]。NSCLC组织中GOLPH3蛋白表达水平在不同的年龄、性别、病理类型、肿瘤细胞分化程度、有无淋巴结转移及肿瘤浸润程度组间的差异均无统计学意义（P>0.05）；单因素及多因素分析结果显示，GOLPH3蛋白高表达与患者不良预后有关。 结论： GOLPH3蛋白高表达在NSCLC发生发展过程中起到重要作用，并与患者不良预后显著相关，可作为肺癌生物学特征和预后判断的参考指标之一。

Objective : To investigate the possible involvement of Golgi phosphoprotein 3 (GOLPH3) in the development and progression of non-small cell lung cancer (NSCLC) by examining the expression of GOLPH3 in cancerous versus noncancerous lung tissue. Methods: Cancerous ( n =116) and para-carcinoma ( n =43, at least 5 cm from the tumor proper) lung tissue specimens were collected from 116 patients with NSCLC who were surgically treated between February, 2004 and February, 2006 in Qilu Hospital of Shandong University． GOLPH3 protein in these specimens was assessed by immunohistochemistry. Possible correlations of the intensity of the immunoreactive GOLPH3 protein signal were various clinical and pathologic variables were analyzed by Cox regression analysis. Results: GOLPH3 protein was detected in 57 8% (67/116) of the cancerous specimens and in 28.0% (12/43) of the non-cancerous specimens ( P ＜0.01). The intensity of the immunoreactive GOLPH3 protein signal was not significantly correlated with any of the clinical and pathological variables assessed ( P >0.05). In addition, univariate and multivariate analysis demonstrated that BRF2 protein overexpression were significantly associated with tumor relapse and prognosis. Conclusion: GOLPH3 is present in a robustly higher rate in cancerous tissue than in non-cancerous lung tissue of patients with NSCLS. The diagnostic and prognostic value of GOLPH3 for NSCLS warrants further investigations.

国家自然科学基金资助项目（No. 30571844）；山东省自然科学基金资助项目（No. ZR2013HM089）；吴阶平医学基金资助项目 （No. 320.6750.12393）